Recent News

• 01.12.2026 - Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
• 12.30.2025 - Cadrenal’s Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
• 12.29.2025 - Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
• 12.17.2025 - Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026
• 12.12.2025 - Cadrenal’s Quiet Expansion Play Is Starting to Get Loud
• 12.12.2025 - Cadrenal’s Anticoagulation Platform Is Expanding in a $40 Billion Market
• 12.11.2025 - Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Recent Filings

• 01.02.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.31.2025 - EFFECT Notice of Effectiveness
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.31.2025 - D Notice of Exempt Offering of Securities
• 12.29.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 12.29.2025 - 144 Report of proposed sale of securities
• 12.23.2025 - 8-K Current report
• 12.23.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.16.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.16.2025 - 424B5 Prospectus [Rule 424(b)(5)]